Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Jiawen FeiDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Xinyue ChangDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Wenjing YangDepartment of Pharmacology and Laboratory of Aging and Nervous Diseases College of Pharmaceutical Sciences of Soochow University Suzhou China.
Yu HeDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Yi LiuDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Mengyao ShiDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Yang LiuDepartment of Cardiology First Affiliated Hospital of Soochow University Suzhou China.ORCID 0009-0002-3303-5018
Xiaoxiao WangDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.ORCID 0009-0002-5551-567X
Hao PengDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.ORCID 0000-0001-6277-662X
Xiaoqing BuDepartment of Epidemiology, School of Public Health and Management Chongqing Medical University Chongqing China.ORCID 0009-0007-4581-0444
Tan XuDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.ORCID 0000-0003-3798-1247
Aili WangDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.
Tian XuDepartment of Neurology Affiliated Hospital of Nantong University Nantong China.ORCID 0000-0001-9278-1622
Yonghong ZhangDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.ORCID 0000-0001-6188-3490
Zhengbao ZhuDepartment of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-Communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Jiangsu Province China.ORCID 0000-0001-5500-0014
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundPhenylacetylglutamine was reported to be associated with ischemic stroke and cognitive performance, but its association with poststroke cognitive impairment (PSCI) remained unclear. We aimed to prospectively investigate the association between plasma phenylacetylglutamine levels and PSCI at 3 months in a multicenter cohort study.
methodsA total of 617 patients with ischemic stroke were included on the basis of a preplanned ancillary study from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). PSCI was evaluated using the Mini-Mental State Examination scale and Montreal Cognitive Assessment scale. Logistic regression analyses were performed to evaluate the association between plasma phenylacetylglutamine and the risk of 3-month PSCI.
resultsAccording to the Mini-Mental State Examination score, a total of 376 participants developed PSCI at 3 months. After adjustment for age, sex, education, and other important risk factors, the multivariable-adjusted odds ratio of PSCI for the highest tertile of phenylacetylglutamine was 2.16 (95% CI, 1.32-3.54;
conclusionsHigh plasma phenylacetylglutamine levels were associated with increased odds of PSCI at 3 months, suggesting that plasma phenylacetylglutamine might be a potential predictive biomarker for PSCI among patients with ischemic stroke.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Plasma Phenylacetylglutamine and Cognitive Impairment After Ischemic Stroke. · full record | OpenQuestion